Skip to content

Study · Randomized controlled trial · 2005

8 results

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman MS, Baron AD

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists1 Jan 2005Cited by 305 (Europe PMC)

PMID15700891 (opens in a new tab)DOI10.1093/ajhp/62.2.173 (opens in a new tab)PepBankPUB-15700891
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In patients with type 2 diabetes, exenatide plasma pharmacokinetic profiles appeared dose proportional in both studies.

    In plain wordsExenatide blood levels appeared proportional to dose in both studies of patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableDose proportionality
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    In both studies, plasma exenatide pharmacokinetic profiles appeared dose proportional.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, exenatide dose-dependently lowered postprandial glucose excursions.

    In plain wordsExenatide reduced blood sugar rises after meals in a dose-dependent manner.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucose excursions
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.02-0.2 microg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide doses of 0.02-0.2 microg/kg dose-dependently lowered postprandial glucose excursions.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, exenatide suppressed postprandial plasma glucagon.

    In plain wordsExenatide lowered glucagon levels after meals in patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial glucagon
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  4. 04HumanRandomized controlled trialMechanism

    In patients with type 2 diabetes, exenatide slowed gastric emptying.

    In plain wordsExenatide slowed stomach emptying in patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGastric emptying
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Gastrointestinal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Exenatide suppressed postprandial plasma glucagon and slowed gastric emptying.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  5. 05HumanRandomized controlled trialSafety outcome

    No serious adverse events occurred in the exenatide studies in patients with type 2 diabetes.

    In plain wordsNo serious side effects occurred in these exenatide studies.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSerious adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse events and no patient withdrawals related to treatment.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  6. 06HumanRandomized controlled trialSafety outcome

    No patients withdrew for treatment-related reasons in the exenatide studies.

    In plain wordsNo patients withdrew for reasons related to treatment in these exenatide studies.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTreatment-related withdrawals
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no serious adverse events and no patient withdrawals related to treatment.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  7. 07HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, nausea was among the most common exenatide adverse events and was mild to moderate.

    In plain wordsNausea was a common exenatide side effect and was mild to moderate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.02-0.2 microg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 microg/kg.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with type 2 diabetes, vomiting was among the most common exenatide adverse events and was mild to moderate.

    In plain wordsVomiting was a common exenatide side effect and was mild to moderate.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.02-0.2 microg/kg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting were the most common adverse events and were mild to moderate in severity at doses ranging from 0.02 to 0.2 microg/kg.
    1 context sentence
    Summary · context
    Two randomized, single-blind, placebo-controlled studies were conducted.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.